OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Integrate validated genomic assays into the clinical management of hormone receptor-positive, node-negative and node-positive early breast cancer.
• Explain the clinical unmet need that underpins ongoing research evaluating therapeutic options for patients with residual disease after neoadjuvant chemotherapy.
• Communicate the benefits and risks of extended adjuvant endocrine therapy for premenopausal and postmenopausal women with ER/PR-positive early breast cancer.
• Appraise the adjunctive role of bisphosphonates in the management of ER-positive and/or PR-positive early breast cancer, and identify patients who may benefit from this course of therapy.
• Demonstrate knowledge of existing treatment strategies and ongoing investigational approaches to the management of triple-negative breast cancer.
• Compare and contrast the efficacy, safety and current clinical utility of anthracycline- and nonanthracycline-based adjuvant chemotherapy regimens, considering HER2 and nodal status of the primary tumor.
• Implement a therapeutic algorithm for the sequential use of combination and/or single-agent chemotherapy that allows multiple lines of treatment for patients with metastatic breast cancer.
• Distinguish those patients with advanced breast cancer who may be eligible for first-line treatment with bevacizumab, and recognize the rationale for ongoing investigation of this agent in the adjuvant setting.
• Develop a strategy for the front-line and subsequent management of HER2-positive metastatic breast cancer, including patients with known CNS involvement.
• Counsel appropriately selected patients with breast cancer about the availability of ongoing clinical trial participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located in our website at ResearchToPractice.com/BCU. ResearchToPractice.com/BCU includes an easy-to-use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc and Sanofi-Aventis.

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Paul E Goss, MD, PhD
- Select publications

Martine J Piccart-Gebhart, MD, PhD
- Select publications

TUMOR PANEL CASE DISCUSSION
- Select publications

INTERVIEWS (continued)

Erica L Mayer, MD, MPH
- Select publications

Maria Theodoulou, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office